Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET | Zendy

Bas B. Koolen | Zendy; Wouter V. Vogel | Zendy; Marcus Peeters | Zendy; Claudette E. Loo | Zendy; Emiel J. Rutgers | Zendy; Renato A. Valdés Olmos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET

Author(s) -

Bas B. Koolen,

Wouter V. Vogel,

Marcus Peeters,

Claudette E. Loo,

Emiel J. Rutgers,

Renato A. Valdés Olmos

Publication year - 2012

Publication title -

journal of oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.228

H-Index - 54

eISSN - 1687-8469

pISSN - 1687-8450

DOI - 10.1155/2012/438647

Subject(s) - medicine , breast cancer , positron emission tomography , fluorodeoxyglucose , radiology , whole body imaging , pet ct , nuclear medicine , cancer

Positron emission tomography (PET), with or without integrated computed tomography (CT), using 18F-fluorodeoxyglucose (FDG) is based on the principle of elevated glucose metabolism in malignant tumors, and its use in breast cancer patients is frequently being investigated. It has been shown useful for classification, staging, and response monitoring, both in primary and recurrent disease. However, because of the partial volume effect and limited resolution of most whole-body PET scanners, sensitivity for the visualization of small tumors is generally low. To improve the detection and quantification of primary breast tumors with FDG PET, several dedicated breast PET devices have been developed. In this nonsystematic review, we shortly summarize the value of whole-body PET/CT in breast cancer and provide an overview of currently available dedicated breast PETs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research